In a phase 3 follow-up of adults given a further Ad5-nCoV dose (n=8266), relative efficacy of two vs one dose against PCR-confirmed COVID-19 was non-significant (34.12%; 95% CI -1.31 to 57.15). At study end, rVE against severe disease was 79.5%.
RCTn = 8,266
Rooyakkers et al. Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial